Skip to main content

Table 3 Burden of care and hospitalization costs in the matched patients

From: Cost-effectiveness of activated protein C in real-life clinical practice

 

All patients (n = 840)

Survivors (n = 471)

Nonsurvivors (n = 369)

 

Pre-license

Post-license

Pre-Post license difference (95% CI)

Pre-license

Post-license

Pre-Post license difference (95% CI)

Pre-license

Post-license

Pre-Post license difference (95% CI)

Omega score

373

427*

54 (9.12 to 98.03)

380

433

53 (-10 to 112)

364

418

54 (-13 to 121)

Reference cost index

2,430

2,862*

432 (187 to 662)

2,254

2,667*

413 (96 to 722)

2,648

3,121*

473 (9 to 936)

ICU stay (day)

21.3

24.4*

3.1 (0.32 to 5.92)

23.8

26.7

2.9 (-0.90 to 6.57)

18.2

21.3

3.1 (-0.89 to 7.25)

Hospital stay (day)

37.9

40.4

2.5 (-1.79 to 6.84)

49.2

51.1

1.9 (-4.41 to 8.37)

24.6

27.5

2.9 (-2.02 to 7.95)

Costs -rhAPC (€)

36,717

41,144

4,427 (-85 to 8,991)

35,575

39,172

3,597 (-1,737 to 8,680)

38,095

43,729

5,634 (-2,005 to 13,380)

Total costs (€)

36,717

47,870*

11,153 (6,601 to 15,709)

35,575

46,752*

11,177 (5,863 to 16,313)

38,095

49,336*

11,241 (3,433 to 19,084)

  1. Values are expressed means and 95% confidence interval (CI) on the means. *P < 0.05 pre-license versus post-license. P < 0.05 post-license survivors versus nonsurvivors. ICU, intensive care unit; rhAPC, recombinant human activated protein C; -rhAPC, without rhAPC acquisition costs.